Twitter Facebook LinkedIn
Center for Global Research Data

Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients

Lead Investigator: Youssef Zeidan, American University of Beirut Medical Center
Title of Proposal Research: Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients
Vivli Data Request: 5932
Funding Source: None
Potential Conflicts of Interest: None

Summary of the Proposed Research:

Although treatment modalities of breast cancer are continuously evolving, evidence for the best treatment combination is still lacking in specific sets of patients. Administration of radiotherapy for HER-2 positive breast cancer patients that have received neoadjuvant targeted therapy/chemotherapy and achieved complete pathological response remains controversial in some clinical scenarios. This creates a clinical dilemma that has to balance the toxicities of radiation against its ability to eradicate probable occult malignant cells that can increase the risk of locoregional recurrence and decrease overall survival rates.

Requested Studies:

A Randomised, Multicentre, Multinational Phase II Study to Evaluate Pertuzumab in Combination With Trastuzumab, Given Either Concomitantly or Sequentially With Standard Anthracycline-based Chemotherapy or Concomitantly With a Non-anthracycline-based Chemotherapy Regimen, as Neoadjuvant Therapy for Patients With Locally Advanced, Inflammatory or Early Stage HER2-positive Breast Cancer
Sponsor: Roche
Study ID: NCT00976989
Sponsor ID: BO22280

A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer
Sponsor: Roche
Study ID: NCT00545688
Sponsor ID: WO20697

Update: This data request was withdrawn on 30 July 2020 by the researcher.